Kornimate/medical-research-clean huggingface dataset:
beetroot juice resistance training older adults

Conditions: Sarcopenia; Old Age; Atrophy

Summary: the present study compared the effects of a nitrate containing beetroot juice supplement (brj+nitrate) vs. a placebo (control) on total and regional fat free mass, quadriceps muscle strength, lower body mobility, and vo2peak in healthy, older adults undergoing a 10-week long progressive resistance training program with protein supplementation.


Eligibility criteria:
inclusion criteria: * able to provide own transportation to study testing visits and intervention * able to read and write in english * nondiabetic, i.e. fasting glucose \< 126 mg/dl * sedentary (less than 60 minutes of moderate intensity structured physical activity each week and occurs in no more than 10 minute blocks and not participating in a resistance exercise training program) * willingness to provide informed consent and participate in intervention. participants with diagnosed depression were permitted to participate provided that they have been medically stable without medication change for at least 3 months. exclusion criteria: * smoking or use of chewing tobacco * involved in another intervention research study * diabetic (type 1 or 2) * atrophic gastritis * hypo- or hyperthyroidism * gout or history of kidney stones * history of hypotension * premenopausal (women) * aversion to study-related testing procedures * allergy/sensitivity/aversion to beetroot beverages or protein supplement * medical conditions with contraindications for engaging in resistance training program or taking the protein supplement * systemic, uncontrolled diseases (diabetes, recent (last 6 months) or current treatment of cancer, thyroid disorders, cardiovascular disease, copd, or inflammatory bowel diseases) * use of any of the following medications: phosphodiesterase type 5 inhibitors, nitroglycerin or nitrate preparations, proton pump inhibitors, or medications for hypothyroidism * potential inability to complete the tasks required for the protocol as well as conditions that may interfere with interpretation of results including: inability to ambulate, severe congestive heart failure or severe cardiovascular disease, neoplasm for practical and neurophysiologic reasons * individuals with contraindications for performing a graded exercise test or have medical contraindications for participating in a scheduled exercise training program * individuals more than 300 pounds or less than 125 pounds due to dexa weight limits and possibility of exceeding recommended daily nitrate dose of 7 mg/kg body weight, respectively.
feasibility of reduction in right sided bowel cancer through contrast enhanced colonoscopy

Conditions: Colorectal Cancer

Summary: the bowel cancer screening program was implemented to address the important issue of prevention and early detection of bowel cancer. results from the first few years of screening and previous smaller studies show that while in its current form it will save many lives, there continue to be polyps and cancers in the upper large bowel (right side) that may be difficult to detect. there is some evidence that these types of polyps (serrated polyps) may be at least partly responsible for cancers missed at the initial colonoscopy and have a faster rate of growth to cancer compared to conventional polyps (adenomas). we propose to examine participants undergoing screening colonoscopy with the addition of a contrast dye ( a safe food colouring agent base already used in various bowel camera procedures in standard clinical practice). this has been shown to improve detection of conventional polyps significantly even though it is considered by some to be more time consuming (possibly taking a few minutes longer) and requiring specific training to undertake. we hope to study the feasibility of undertaking these procedures to improve detection and removal of these polyps within the bowel screening program and potentially inform further studies to assess the impact of improved detection and consequent potentially reduced incidence of interval or missed bowel cancers in longer term follow up. thus the main aims of this feasibility study are to assess if this type of procedure would be feasible to implement and acceptable to participants, colonoscopists and the screening program and also assess any additional time or costs involved to inform the question of if a larger study should then be undertaken to conclusively prove or disprove the merits of this approach in terms of health economics, cancer detection and survival.


Eligibility criteria:
inclusion criteria: * all participants testing positive on faecal occult blood test (fobt) in the screening program who are eligible and appropriate for an index screening colonoscopy will be offered participation in the study. * all participants attending for a one year surveillance colonoscopy if they have undergone an index screening colonoscopy as part of the study as per current guidelines for surveillance will also be offered inclusion exclusion criteria: * any participants not deemed fit for colonoscopy on the screening program or undergoing alternative investigation such as ct pneumocolon or minimal prep ct scan as their index procedure instead. * participants who have undergone previous colorectal surgery will be excluded from the study though their standard management in the screening program will continue unchanged.
trial of jmkx003142 in participants with rapidly progressive autosomal dominant polycystic kidney disease (adpkd)

Conditions: ADPKD (autosomal Dominant Polycystic Kidney Disease)

Summary: a phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of jmkx003142 in participants with rapidly progressive autosomal dominant polycystic kidney disease (adpkd)

evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of jmkx003142 in participants with rapidly progressive adpkd

Eligibility criteria:
inclusion criteria: * able to understand the procedures of this trial and provide written informed consent voluntarily; * age between 18 to 55 years, male or female; * adpkd diagnostic criteria were met before randomization; * rapidly progressive adpkd criteria were met. exclusion criteria: * 12 weeks prior to screening, patients had taken tolvaptan or another adpkd improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period; * praticipants who are unable to feel thirst, or have difficulty with fluid/food intake; * patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the icf; * the investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.
bmi and ultrasound/clinical assessments of ra disease activity

Conditions: Obsessional Erotomania

Summary: comparison of the level of agreement between power doppler ultrasound measured number of synovitis (≥ grade 1 on a semi-quantitative scale) and clinically defined number of swollen joints in obese (i.e. bmi\>30) versus normally weighted ra patients.

clinical evaluation of synovitis in rheumatoid arthritis (ra) is difficult in obese and overweighted patients, due to the fat pad located around the joint, that can over- or under estimate the number of joints regarded as swollen by clinical examination. ra in obese and overweighted patients has several distinctive characteristics as compared to the disease observed in normally weighted subjects: diease activity (assessed by composites scores such as disease activity score (das28) or simple disease activity index (sdai)) is higher, while response to treatment and severity (asessed by radiographic progression) are lower. objectives: primary end point: comparison of the level of agreement between the number of joints considered abnormal by power doppler ultrasound synovitis (≥ grade 1 on a semi-quantitative scale) and clinical examination (swollen joint count (sjc) as componant of sdai) in obese (i.e. bmi\>30) versus normally weighted ra patients. secondary end points : * comparison of the level of agreement between clinical and ultrasound findings in overweighted versus normally weighted patients, when joint count evaluation is based on another composite index ((das28-crp et das44-crp), based on the number of tender joints, and based on a joint by joint evaluation * comparison of agreement between obese and non obese * evaluation of the impact of other factors than bmi on the level of agreement between power doppler ultrasound defined number of synovitis and clinically defined swollen joint count * reliability between ultrasound and clinical examination across the different investigation centers study design: prospective multicenter observational study inclusion criteria: ra patients fulfilling acr/eular 2010 criteria exclusion criteria: patient simultaneously included in another study with blinded treatment; steinbrocker class iv patients outcome measure : level of agreement between sjc and power doppler us synovitis

Eligibility criteria:
inclusion criteria: * ra patients fulfilling acr/eular 2010 criteria exclusion criteria: * patient simultaneously included in another study with blinded treatment; steinbrocker class iv patients, pregnancy.
study of using the hyper-cl™ lens (hyper osmotic contact lens) in subjects suffering from corneal edema

Conditions: CORNEAL EDEMA

Summary: the hyper-cl™ lenses are indicated for therapeutic use as a bandage to protect the corneal surface and to relieve corneal pain in the treatment of acute or chronic ocular pathologies, such as bullous keratopathy, corneal erosions, entropion, corneal edema, and corneal dystrophies as well as post-surgical conditions resulting from cataract extraction and corneal surgery. the lenses may be prescribed for daily wear with removal for cleaning and disinfection (chemical, not heat) prior to reinsertion, as recommended by the eye care professional. in addition hyper-cl™ contact lenses can also provide optical correction during healing if required.

this study is a prospective, randomized crossover study. the primary aim of this study is to assess the safety and effectiveness of using the hyper-cl™ lens +salt solution (5% nacl) as compared with using regular contact lens + salt solution (5% nacl) in subjects suffering from corneal edema. safety will be assessed by evaluating the rate of adverse events and adverse device effects occurred throughout the study period. effectiveness will be assessed by measuring changes in corneal thickness and visual acuity. subjects with corneal edema will be the study population. only subjects who have signed the informed consent form and meet all the eligibility criteria listed below will be qualified for enrollment. the study will encompass a total of up to 80 subjects who will complete the protocol follow-up schedule. each subject will be treated with: treatment a: hyper-cl™ lens + salt solution + antibiotics drops (7 days) treatment b: regular soft contact lens +salt solution+ antibiotics drops (7 days) one week (7 days) of washout without any treatment will be between treatments. subject will be equally allocated to one of the following 2 crossover regimen based on a randomization scheme with blocks stratified by center: a-b; b-a

Eligibility criteria:
inclusion criteria: 1. subject is over 18 years old 2. subject with corneal edema in the visual access 3. subject with visual acuity of 6/20 or worse (equivalent etdrs) clinically explained by corneal edema 4. subject understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed. exclusion criteria: 1. subject with active herpes keratitis 2. subject with scarred cornea 3. subject who is suffering from erosions and/or infections of the cornea (red eye) 4. subject with glaucoma shunts (e.g. ahmed valve) and or bleb 5. subject who require chronic administration of any topical ophthalmic beside lubrication eye drops and steroids or anti glaucoma drags 6. subject who is currently participating or have participated in an investigational study, other than this study, within the past 60 days
5% and 15% dextrose prolotherapy efficacy in lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: in the treatment of lateral epicondylitis, 5% dextrose prolotherapy is aimed to be more reliable than 15% prolotherapy in terms of side effects and to show that it is similar in terms of efficacy in treatment.

for this prospective randomized controlled study, volunteer patients who met the inclusion criteria and applied to the health sciences university, istanbul physical therapy and rehabilitation training and research hospital, physical medicine and rehabilitation outpatient clinic will be included in the study. participants who volunteered for the study will be divided into study groups and control groups by stratified randomization. a total of 26 volunteers will be recruited. a solution to be used for prolotherapy is containing 30% dextrose, 2% lidocaine, and physiological saline. in the beginning, all patients were asked about gender, age, body mass index, education level, occupation, duration of complaint, dominant side and affected extremity, previous treatments, and when the last treatment was applied. patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week. prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact. patients in the control group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose, initially (0.) week 3 and week 6. the injection will be made with the same method as the study group. measurements; will be evaluated at baseline (week 0), immediately after treatment at week 3, week 6, and week 12. patients; in the evaluation of the visual analog scale (vas), quick disabilities of the arm, shoulder and hand (qdash), grip strength, hand dynamometer measurements, and adverse events during the study period will be noted.

Eligibility criteria:
inclusion criteria: * pain score ≥3 according to vas for more than 3 months in the lateral elbow joint * tenderness on palpation over the lateral epicondyle * positiveness in at least two of the tests specific to lateral epicondylitis(le) (mills test, resistant middle finger extension and cozen test), * \> 20 years old , \< 60 years old exclusion criteria: * patients who received physical therapy modalities and/or steroid injections in the last 3 months, * having a history of malignancy, * pregnant cases, * those who have bone and joint diseases in the neck, shoulder and elbow, * patients with infection in the treatment area, * patients with arrhythmia or pacemaker in the heart, * patients receiving coagulation disorder or anticoagulant therapy, * those with local dermatological problems, * patients with a history of surgery in the elbow joint, * having a tendon tear * presence of nerve involvement * lack of cooperation and refusal to participate in the study due to cognitive dysfunction

Keywords: lateral epicondylitis dextrose prolotherapy pain injection
effectiveness of levonorgestrel-intrauterine system (lng-ius) versus depot medroxyprogesterone acetate (dmpa) in treatment of pelvic pain in clinically diagnosed endometriotic patients

Conditions: Clinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS

Summary: the primary objective : to compare effectiveness of pain control in endometriosis associated pelvic pain between lng-ius and dmpa the secondary objective : to compare vaginal bleeding pattern, side effect, continuation rate, satisfaction and quality of life between lng-ius and dmpa in treatment of endometriosis associated pelvic pain

the participants were randomized into two treatment groups, by block of four method, lng-ius and dmpa group. for the patients in the lng-ius group, a lng-ius (mirena) was inserted. the system released the active ingredient lng for up to five years at a virtually constant rate. for the patients in the depot mpa group, 150 mg depot mpa was given intramuscularly once every three months. all participants were recieved the individual calendars to record all vaginal bleeding occured during treatment. the amount of bleeding was described relative to normal menstruation of each patient; less than, same as, more than their baseline menses. to use easily, we assigned the symbols to represent quantity of vaginal bleeding as described. each symbol was recorded every day except no bleeding, which was represented with blank space in the calendar. the bleeding pattern were assessed as bleeding rating score; less than normal menses = 1, same amount of normal menses = 2, more than normal menses = 3. no bleeding was defined as 30 consecutive days with bleeding score 0. the mean bleeding score was calculated by sum of the daily scores in each month period. follow-up visits were scheduled three times at months 1, 3 and 6 after initial treatment. at each visit, vas and bleeding pattern was recorded. side-effects of the two therapies were checked. patients were allowed to choose to withdraw from their designated therapy at any time. the follow-up was completed in may 2016 for the last patient. at the final visit, 6 months after treatment, all participants in both treatment groups were recorded the datas of blood pressure, body weight, transvaginal ultrasonography, lipid profiles and sf-36 quesionaires. in addition, all50 patients were asked whether they want to continue in the given treatement and the reason of discontinuation including the satisfaction scores during therapy were rated as 1-5 likert-scale; 1-very dissatisfied, 2- dissatisfied, 3-neither satisfied/dissatisfied, 4-satisfied, 5-very satified.

Eligibility criteria:
inclusion criteria: * age 18-45year pelvic pain vas\>50 previous sexual intercouse exclusion criteria: * other genital tract disease causing pelvic pain previous hromonal treament 3 month history of dmpa treatment failure who eligibility criteria 2009 categorized in 3-4 for dmpa and lng-ius user fertility desire within 1 year psychoneurosis pregnant and breast fed women
prediction of fluid responsiveness in children undergoing major surgery

Conditions: Hypovolemia

Summary: the purpose of this study is to evaluate predictability of a respiratory variation in pulse oximeter plethysmography for fluid responsiveness in children undergoing major surgery.

the purpose of this study is to evaluate predictability of a a respiratory variation in pulse oximeter plethysmography (delta pop) for fluid responsiveness in children undergoing major surgery. when there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmhg, the study will be started. at index fingers of both hand, pulse oximeter sensors are applied by gradually increasing the contact force (from 0 to 1.4n, being increased by 0.2-0.3n). then, pulse oximeter plethysmography (pop) waveforms are obtained for 90 seconds. then, intravenous crystalloid fluid 10 ml/kg is infused for 15 min. to evaluate the change of cardiac output, transesophageal or transthoracic echocardiography is performed before and after fluid administration. in addition, hemodynamic parameters including pulse pressure variation, systolic pressure variation, pleth variability index and central venous pressure are also recorded before and after fluid administration. finally, patients will be divided into fluid responder group and non-responder group. if stroke volume index measured using echocardiography increases over 15% after fluid administration, the patient will be fluid responder. delta pop (%) obtained from each finger with different contact force is calculated as follows;(popmax - popmin)/{(popmax + popmin)/2}. using receiver operating characteristic curve, diagnostic power of delta pops from different contact forces for fluid responsiveness will be evaluated. in addition, difference between delta pop from low contact force and that from high contact force will be evaluated.

Eligibility criteria:
inclusion criteria: - children who will be scheduled for major surgery requiring invasive hemodynamic monitoring exclusion criteria: * renal, hepatic and pulmonary disease * preoperative infection: increased c-reactive protein, whith blood cell count over 10,000, and with fever * genetic and hematologic disease * ventricular dysfunction * increased intracranial pressure
a dose evaluation study for the latanoprost punctal plug delivery system (l-ppds) in subjects with ocular hypertension or open-angle glaucoma

Conditions: Glaucoma; Ocular Hypertension (OH)

Summary: the purpose of this study is to evaluate the efficacy, safety and duration of the l-ppds (latanoprost punctal plug delivery system) at different dose levels.


Eligibility criteria:
inclusion criteria: * male or female at least 18 years old * diagnosis of bilateral open angle glaucoma or ocular hypertension * unmedicated iop must be ≥22mm hg exclusion criteria: * any significant vision loss in the last year * no contact lens use for the length of the study * abnormal eye lids, eye infection, or diseases to the eye * recent eye surgery * uncontrolled medication conditions
covid-19-associated anxiety of pregnant women for anomalies, stillbirth and preterm labor

Conditions: Anxiety State

Summary: capture of anxiety for anomalies, stillbirth and preterm labor of pregnant women during covid-19 pandemia


Eligibility criteria:
inclusion criteria: * consenting ability exclusion criteria: * language barrier * uncompleted questionary
pragmatic approach to esophageal dilation

Conditions: Dysphagia; Swallowing Disorders

Summary: the purpose of this study is to better understand the role of a technique called esophageal dilation in patients who complain of trouble swallowing. in patients with esophageal stricture we want to determine if the size of the esophageal dilator makes a difference in symptoms and outcomes. in patients who do not have an obvious esophageal stricture we want to determine if esophageal dilation is an effective therapy in these patients.


Eligibility criteria:
inclusion criteria: 1. patients with esophageal dysphagia who are 18 years old or older. 2. patients with dysphagia undergoing esophagogastroduodenoscopy (egd). 3. patients who are able to provide consent for the study. 4. patients with known esophageal stricture that may have or may not have been dilated before. exclusion criteria: 1. patients with malignant stricture. 2. pregnant women. 3. patients with a personal history of esophageal perforation. 4. patients with achalasia, or globus sensation. 5. any accessory procedures, like esophageal stenting, excision, steroid injection, or dysphagia treatment currently being done at outside facility.

Keywords: dysphagia swallowing disorders empirical dilation dilation dysphagia score diet score